Healthcare

🧠 - Heidelberg scientists have identified a protein pairing that acts as a molecular "death switch" in Alzheimer's disease, and a new compound can break it apart, protecting neurons even as it reduces amyloid. 🧬 - The first-ever human trial of partial epigenetic reprogramming is now enrolling, with Life Biosciences testing ER-100 in patients with retinal degeneration in a trial that could redefine what it means to treat aging at the cellular level. 💊 - GLP-1 receptor agonists do not cause disproportionate muscle loss, and new data shows they actually increase mitochondrial proteins in skeletal muscle, suggesting metabolic benefits that go well beyond weight reduction. 🦠 - Gut bacteria are actively injecting proteins into human intestinal cells via molecular syringes, and this mechanism appears more prevalent in people with Crohn's disease, pointing to a new pathway for understanding and treating chronic gut inflammation. ⌚ - ARPA-H's new Delphi program is funding wearable biosensors that can continuously track cytokines and hormones in real time, a potential leap from tracking symptoms to detecting the earliest biological signals of disease and aging.

❤️ New ACC/AHA guidelines recommend cardiovascular screening starting at age nine and statin consideration at 30, with evolocumab cutting first heart attacks by 31 percent in diabetes patients. 🤖 Eli Lilly's $2.75 billion deal with Insilico Medicine marks the largest AI drug discovery partnership ever, as over 173 AI-discovered drugs advance through clinical trials toward the first potential FDA approval. 🦠 A gut bacteria compound called Bac429 doubled cancer immunotherapy response in resistant lung tumors and is now being prepared for human testing. 😴 A study of nearly 39,000 adults proved that combining morning sunlight, time-restricted eating, Zone 2 exercise, and five minutes of breathwork significantly improves sleep, fitness, and nervous system resilience. ⛰️ Multi-biomarker wearables combining glucose, heart, temperature, and activity sensing are launching in 2026, while the first needle-free CGM has received FDA clearance.